OBJECTIVE: To evaluate a contribution of selected laboratory parameters for a prediction of progressive and erosive development in patients with early rheumatoid arthritis (RA). METHODS: In a prospective study baseline levels of antibodies to cyclic citrullinated peptide (anti-CCP), IgM, IgA, and IgG rheumatoid factors (RFs) were measured by enzyme linked immunosorbent assay (ELISA) in 104 patients with RA with disease duration <2 years. Antikeratin antibodies (AKA) and antiperinuclear factor (APF) were detected by indirect immunofluorescence. Patients were divided into two groups based either on the presence or absence of erosions or according to progression of Larsen score at the end of the 24 months' follow up. RESULTS: Sixty seven (64%) patients developed radiographic erosions, 49 (47%) had progression in Larsen score, and 36 (35%) progressed by more than 10 Larsen units. Significant differences in erosions and progression between the two groups were detected for anti-CCP, AKA, APF, IgM RF, IgA RF, and IgG RF. Baseline Larsen score correlated significantly with anti-CCP, IgM RF, and IgA RF levels, and all measured antibodies correlated with the progression >10 units. The combination of anti-CCP and IgM RF increased the ability to predict erosive and progressive disease. CONCLUSION: The data confirmed that measurement of anti-CCP, AKA, APF, and individual isotypes of RFs was useful for prediction of structural damage early in the disease course. Combined analysis of anti-CCP and IgM RF provides the most accurate prediction.
OBJECTIVE: To evaluate a contribution of selected laboratory parameters for a prediction of progressive and erosive development in patients with early rheumatoid arthritis (RA). METHODS: In a prospective study baseline levels of antibodies to cyclic citrullinated peptide (anti-CCP), IgM, IgA, and IgG rheumatoid factors (RFs) were measured by enzyme linked immunosorbent assay (ELISA) in 104 patients with RA with disease duration <2 years. Antikeratin antibodies (AKA) and antiperinuclear factor (APF) were detected by indirect immunofluorescence. Patients were divided into two groups based either on the presence or absence of erosions or according to progression of Larsen score at the end of the 24 months' follow up. RESULTS: Sixty seven (64%) patients developed radiographic erosions, 49 (47%) had progression in Larsen score, and 36 (35%) progressed by more than 10 Larsen units. Significant differences in erosions and progression between the two groups were detected for anti-CCP, AKA, APF, IgM RF, IgA RF, and IgG RF. Baseline Larsen score correlated significantly with anti-CCP, IgM RF, and IgA RF levels, and all measured antibodies correlated with the progression >10 units. The combination of anti-CCP and IgM RF increased the ability to predict erosive and progressive disease. CONCLUSION: The data confirmed that measurement of anti-CCP, AKA, APF, and individual isotypes of RFs was useful for prediction of structural damage early in the disease course. Combined analysis of anti-CCP and IgM RF provides the most accurate prediction.
Authors: P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini Journal: N Engl J Med Date: 2000-11-30 Impact factor: 91.245
Authors: E J Kroot; B A de Jong; M A van Leeuwen; H Swinkels; F H van den Hoogen; M van't Hof; L B van de Putte; M H van Rijswijk; W J van Venrooij; P L van Riel Journal: Arthritis Rheum Date: 2000-08
Authors: S Muñoz-Fernández; R Alvarez-Doforno; J M González-Tarrio; A Balsa; P Richi; G Fontán; J Gijón-Baños; E Martin-Mola Journal: J Rheumatol Date: 1999-12 Impact factor: 4.666
Authors: G Hayem; P Chazerain; B Combe; A Elias; T Haim; P Nicaise; K Benali; J F Eliaou; M F Kahn; J Sany; O Meyer Journal: J Rheumatol Date: 1999-01 Impact factor: 4.666
Authors: R Goldbach-Mansky; J Lee; A McCoy; J Hoxworth; C Yarboro; J S Smolen; G Steiner; A Rosen; C Zhang; H A Ménard; Z J Zhou; T Palosuo; W J Van Venrooij ; R L Wilder; J H Klippel; H R Schumacher; H S El-Gabalawy Journal: Arthritis Res Date: 2000-03-31
Authors: Max Brenner; Teresina Laragione; Anish Shah; Adriana Mello; Elaine F Remmers; Ronald L Wilder; Pércio S Gulko Journal: Arthritis Rheum Date: 2012-05
Authors: J-E Gottenberg; S Mignot; P Nicaise-Rolland; J Cohen-Solal; F Aucouturier; J Goetz; C Labarre; O Meyer; J Sibilia; X Mariette Journal: Ann Rheum Dis Date: 2004-07-01 Impact factor: 19.103
Authors: B Combe; R Landewe; C Lukas; H D Bolosiu; F Breedveld; M Dougados; P Emery; G Ferraccioli; J M W Hazes; L Klareskog; K Machold; E Martin-Mola; H Nielsen; A Silman; J Smolen; H Yazici Journal: Ann Rheum Dis Date: 2006-01-05 Impact factor: 19.103
Authors: L Caponi; E Petit-Teixeira; M Sebbag; F Bongiorni; S Moscato; F Pratesi; C Pierlot; J Osorio; S Chapuy-Regaud; M Guerrin; F Cornelis; G Serre; P Migliorini Journal: Ann Rheum Dis Date: 2004-10-14 Impact factor: 19.103
Authors: F Jouen; O Vittecoq; F Leguillou; I Tabti-Titon; J F Menard; O Mejjad; S Pouplin; P Boumier; P Fardellone; A Gayet; D Gilbert; F Tron; X Le Loët Journal: Clin Exp Immunol Date: 2004-09 Impact factor: 4.330
Authors: J van Holten; K Pavelka; J Vencovsky; H Stahl; B Rozman; M Genovese; A J Kivitz; J Alvaro; G Nuki; D E Furst; G Herrero-Beaumont; I B McInnes; P Musikic; P P Tak Journal: Ann Rheum Dis Date: 2004-07-08 Impact factor: 19.103